Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-05-06 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin receives approval from U.S. FDA for Travoprost Opthalmic Solution USP.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product. It is addressed to stock exchanges and references a regulatory disclosure under SEBI Listing Regulations. The content is a corporate announcement about a regulatory milestone and product approval, not a financial report, earnings release, or detailed investor presentation. The document length is 4326 characters, which is relatively short and typical for a press release. There is no detailed financial data, management discussion, or regulatory filing beyond the announcement itself. Therefore, this document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2024-05-06 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges and references a disclosure pursuant to SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and product marketing, not a financial report, earnings release, or detailed investor presentation. The document length is 4326 characters, which is relatively short and typical for a press release. There is no financial data, no management discussion, no voting results, no audit information, and no detailed report attached or referenced as being published. Therefore, this document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and disclosure under listing obligations, not a formal financial or governance report.
2024-05-06 English
Intimation regarding loss of share certificate by the shareholders.
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the stop transfer request received from investors. It is addressed to stock exchanges and signed by the company secretary. The content is regulatory compliance related to share certificate handling and does not contain financial data, management discussion, or report publication. It is not an annual report, earnings release, or any financial report. It is a regulatory filing related to compliance with listing obligations.
2024-05-06 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the request for stop transfer, addressed to stock exchanges. The document is short (2876 characters) and is a regulatory compliance communication rather than a financial report or announcement of voting results, management changes, or capital changes. It does not contain financial data, earnings, or management discussion. It fits best under Regulatory Filings (RNS) as a compliance certificate filing under SEBI regulations.
2024-05-06 English
Intimation Under Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Regulatory Filings Classification · 100% confidence The document is a formal disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the receipt of an order imposing a penalty by a tax authority. The document includes details of the order, the authority, the nature of the penalty, and the company's response. It does not contain financial statements, audit results, or detailed financial performance data. It is a regulatory announcement about a legal/tax matter rather than a full report or financial filing. The document length is under 5,000 characters and serves as an official regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS).
2024-05-01 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It informs about the receipt of an order imposing a penalty by a tax authority (Office of the Deputy Commissioner of State Tax, Orissa GST Authority). The document includes details of the penalty, the company's position on the matter, and states that there is no material impact on the company's financials or operations. The document is a regulatory announcement about a legal/tax matter and does not contain financial statements, earnings data, or detailed management discussion. It is not a full report but a compliance disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.